APA (7th ed.) Citation

Adam, D. N., Jablonski Bernasconi, M. Y., Thoning, H., & Wu, J. J. (2022). Matching-Adjusted Indirect Comparison of Long-Term Efficacy and Safety Outcomes for Calcipotriol Plus Betamethasone Dipropionate Foam Versus Halobetasol Proprionate Plus Tazarotene Lotion in the Treatment of Plaque Psoriasis. Dermatology & Therapy, 12(11), 2589. https://doi.org/10.1007/s13555-022-00824-9

Chicago Style (17th ed.) Citation

Adam, David N., Marie Y. Jablonski Bernasconi, Henrik Thoning, and Jashin J. Wu. "Matching-Adjusted Indirect Comparison of Long-Term Efficacy and Safety Outcomes for Calcipotriol Plus Betamethasone Dipropionate Foam Versus Halobetasol Proprionate Plus Tazarotene Lotion in the Treatment of Plaque Psoriasis." Dermatology & Therapy 12, no. 11 (2022): 2589. https://doi.org/10.1007/s13555-022-00824-9.

MLA (9th ed.) Citation

Adam, David N., et al. "Matching-Adjusted Indirect Comparison of Long-Term Efficacy and Safety Outcomes for Calcipotriol Plus Betamethasone Dipropionate Foam Versus Halobetasol Proprionate Plus Tazarotene Lotion in the Treatment of Plaque Psoriasis." Dermatology & Therapy, vol. 12, no. 11, 2022, p. 2589, https://doi.org/10.1007/s13555-022-00824-9.